Breaking News

AGC Biologics Expands Its Yokohama, Japan Facility

The new site adds two Singe-Use Bioreactors from Thermo Scientific.

By: Rachel Klemovitch

Assistant Editor

CDMO, AGC Biologics, announced a strategic decision about the large-scale single-use technology it will use at its new Yokohama, Japan facility. The company added two 5,000 L Thermo Scientific DynaDrive Single-Use Bioreactors (S.U.B.), with GMP operations beginning in 2027. The Yokohama facility is expected to help maximize operational and supply chain efficiencies across AGC Biologics’ global network by adding another site in the region. AGC Biologics’ Yokohama facility will offer s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters